DE3789413D1 - Lymphokin-ähnliche Peptide. - Google Patents
Lymphokin-ähnliche Peptide.Info
- Publication number
- DE3789413D1 DE3789413D1 DE87810561T DE3789413T DE3789413D1 DE 3789413 D1 DE3789413 D1 DE 3789413D1 DE 87810561 T DE87810561 T DE 87810561T DE 3789413 T DE3789413 T DE 3789413T DE 3789413 D1 DE3789413 D1 DE 3789413D1
- Authority
- DE
- Germany
- Prior art keywords
- lymphokine
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/70—Vector systems having a special element relevant for transcription from fungi
- C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB868623850A GB8623850D0 (en) | 1986-10-03 | 1986-10-03 | Lymphokine related peptide |
GB868628358A GB8628358D0 (en) | 1986-11-27 | 1986-11-27 | Lymphokine related peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3789413D1 true DE3789413D1 (de) | 1994-04-28 |
DE3789413T2 DE3789413T2 (de) | 1994-07-28 |
Family
ID=26291377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3789413T Expired - Fee Related DE3789413T2 (de) | 1986-10-03 | 1987-09-28 | Lymphokin-ähnliche Peptide. |
Country Status (11)
Country | Link |
---|---|
US (2) | US5350687A (de) |
EP (1) | EP0263072B1 (de) |
JP (1) | JPH09188698A (de) |
AU (1) | AU7930987A (de) |
DE (1) | DE3789413T2 (de) |
DK (1) | DK517787A (de) |
ES (1) | ES2052602T3 (de) |
FI (1) | FI874287A (de) |
IE (1) | IE61773B1 (de) |
NO (1) | NO874159L (de) |
PT (1) | PT85849B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2750604B1 (fr) * | 1996-07-02 | 2002-09-20 | Oreal | Heteromere liant l'acide arachidonique et son utilisation en cosmetique ou pharmacie |
WO1990011301A1 (en) * | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
GB8915414D0 (en) * | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
JP2747839B2 (ja) * | 1989-08-14 | 1998-05-06 | 花王株式会社 | モノクローナル抗体 |
US5149544A (en) * | 1989-11-13 | 1992-09-22 | Research Corporation Technologies, Inc. | Method of inhibiting progenitor cell proliferation |
DE69133159D1 (de) * | 1990-09-05 | 2003-01-02 | Heart Res Inst Ltd | Chemotaktische faktoren |
CH685959A5 (de) * | 1992-08-24 | 1995-11-15 | Biomedicals Ag | Diagnostische Testpackung zur Bestimmung von Proteinen. |
US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
US5776348A (en) * | 1995-02-07 | 1998-07-07 | Massachusetts Institute Of Technology | Mineral precipitation system and method for inhibiting mineral precipitate formation |
WO1998031799A2 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | Polynucleotides and polypeptides encoding receptors |
US6706683B1 (en) | 1998-09-29 | 2004-03-16 | Asahi Kasei Pharma Corporation | Method for controlling the release of granules |
AU773265B2 (en) * | 1998-11-05 | 2004-05-20 | Regents Of The University Of Michigan, The | S100 proteins and autoantibodies as serum markers for cancer |
MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
AU2003212246A1 (en) * | 2002-02-15 | 2003-09-04 | Johannes Roth | Method for diagnosis of inflammatory diseases using mrp8/mrp14 |
DE60327075D1 (de) | 2002-07-05 | 2009-05-20 | Univ Laval | Der entzündungsreaktionen |
TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
US7361474B2 (en) * | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
WO2004084928A1 (en) | 2003-03-28 | 2004-10-07 | UNIVERSITé LAVAL | S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment |
MXJL06000006A (es) | 2003-08-22 | 2006-05-04 | Avanir Pharmaceuticals | Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre. |
CA2557503A1 (en) * | 2004-02-25 | 2005-09-09 | The United States Of America, As Represented By The Department Of Vetera Ns Affairs | Methods for diagnosing and treating bladder cancer |
SE0400886D0 (sv) * | 2004-04-02 | 2004-04-02 | Amersham Biosciences Ab | Process of purification |
CA2573596A1 (en) * | 2004-07-13 | 2006-01-19 | Universite Laval | S100 protein inhibitors for treating leukemia |
SG150497A1 (en) | 2004-07-23 | 2009-03-30 | Aspenbio Pharma Inc | Methods and devices for diagnosis of appendicitis |
US7659087B2 (en) | 2004-07-23 | 2010-02-09 | Aspenbio Pharma, Inc. | Methods and devices for diagnosis of appendicitis |
CA2600175A1 (en) * | 2005-03-24 | 2006-03-20 | Avanir Pharmaceuticals | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
GB0605689D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
EP3075867B1 (de) * | 2008-09-03 | 2019-03-13 | Quantumdx Group Limited | Wahrnehmungsstrategien und verfahren zum nukleinsäurenachweis mit biosensoren |
EP2711682B1 (de) | 2011-05-20 | 2019-07-10 | Riken | Klärungsreagens für biologische materialien und verwendung davon |
EP2748613B1 (de) | 2011-10-07 | 2021-05-05 | Baxalta GmbH | Oxmif als diagnosemarker |
US10626166B2 (en) * | 2014-08-22 | 2020-04-21 | Baxalta Incorporated | Detection of CHO-MIF contaminations |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE230876C (de) * | ||||
US4322274A (en) * | 1980-08-28 | 1982-03-30 | Wilson Gregory B | Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene |
GB2125047B (en) | 1982-08-09 | 1986-02-19 | Ciba Geigy Ag | Yeast hybrid vectors and their use for the production of polypeptides |
GB8318754D0 (en) * | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
JPS6041697A (ja) * | 1983-08-15 | 1985-03-05 | Asahi Chem Ind Co Ltd | 活性蛋白質誘導体の新規合成法 |
DE3479520D1 (en) | 1983-11-21 | 1989-09-28 | Ciba Geigy Ag | Synthesis of tissue plasminogen activator(tpa) by yeast |
CA1297437C (en) | 1983-11-21 | 1992-03-17 | Hans Rink | Process for the preparation of protease inhibitors |
JPH0672158B2 (ja) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
GB8915414D0 (en) * | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
-
1987
- 1987-09-28 DE DE3789413T patent/DE3789413T2/de not_active Expired - Fee Related
- 1987-09-28 ES ES87810561T patent/ES2052602T3/es not_active Expired - Lifetime
- 1987-09-28 EP EP87810561A patent/EP0263072B1/de not_active Expired - Lifetime
- 1987-09-30 FI FI874287A patent/FI874287A/fi not_active IP Right Cessation
- 1987-10-01 PT PT85849A patent/PT85849B/pt not_active IP Right Cessation
- 1987-10-02 NO NO874159A patent/NO874159L/no unknown
- 1987-10-02 AU AU79309/87A patent/AU7930987A/en not_active Abandoned
- 1987-10-02 DK DK517787A patent/DK517787A/da not_active Application Discontinuation
- 1987-10-02 IE IE264587A patent/IE61773B1/en not_active IP Right Cessation
-
1990
- 1990-11-21 US US07/617,485 patent/US5350687A/en not_active Expired - Fee Related
-
1995
- 1995-07-27 US US08/508,142 patent/US5702920A/en not_active Expired - Fee Related
-
1996
- 1996-12-18 JP JP8338746A patent/JPH09188698A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NO874159D0 (no) | 1987-10-02 |
US5702920A (en) | 1997-12-30 |
FI874287A (fi) | 1988-04-04 |
US5350687A (en) | 1994-09-27 |
DE3789413T2 (de) | 1994-07-28 |
JPH09188698A (ja) | 1997-07-22 |
ES2052602T3 (es) | 1994-07-16 |
DK517787D0 (da) | 1987-10-02 |
EP0263072A2 (de) | 1988-04-06 |
NO874159L (no) | 1988-04-05 |
DK517787A (da) | 1988-04-04 |
IE872645L (en) | 1988-04-03 |
FI874287A0 (fi) | 1987-09-30 |
IE61773B1 (en) | 1994-11-30 |
PT85849A (en) | 1987-11-01 |
EP0263072A3 (en) | 1990-01-10 |
EP0263072B1 (de) | 1994-03-23 |
AU7930987A (en) | 1988-05-19 |
PT85849B (pt) | 1990-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3789413D1 (de) | Lymphokin-ähnliche Peptide. | |
ATE110743T1 (de) | Antikoagulierende peptide. | |
DK97790D0 (da) | Renin-inhiberende peptider | |
NO892294D0 (no) | Polypeptidforbindelser. | |
NO881384L (no) | Peptider. | |
NO885108D0 (no) | Peptider. | |
DK197989A (da) | Peptidanaloger | |
DK531986D0 (da) | Peptider | |
DK354487A (da) | Oncogen-relaterede peptider | |
DK253087A (da) | Syntetiske natriuretiske peptider | |
IT8821556A0 (it) | Peptidi immunostimolanti. | |
DE3586765D1 (de) | Immunogenische hav-peptide. | |
FI851488L (fi) | Peptider. | |
KR900700503A (ko) | 펩티드 | |
DE3685636D1 (de) | Lysozymbetreffende peptide. | |
DE3780388D1 (de) | Fsh-stimulierendes peptid. | |
NO872386D0 (no) | Peptider. | |
DE3869939D1 (de) | Biologisch wirksame peptide. | |
ATE103339T1 (de) | Lymphokin-aehnliche peptide. | |
DE68914057D1 (de) | Peptide. | |
IT8821191A0 (it) | Peptidi anoressizzanti e ipotensivi. | |
NO883008D0 (no) | Peptidforbindelser. | |
DE3774988D1 (de) | Peptidderivate. | |
NO910981D0 (no) | Peptidforbindelser. | |
DE69006311D1 (de) | Antimetastatische peptide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH |
|
8339 | Ceased/non-payment of the annual fee |